A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Orr, Mark T ^a   Beebe, Elyse A ^a   Hudson, Thomas E ^a   Moon, James J ^b   Fox, Christopher B ^a   Reed, Steven G ^a   Coler, Rhea N ^a,c  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 5; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; IMMUNOGENICITY; MACROPHAGE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NANOEMULSION; NONHUMAN; SIGNAL TRANSDUCTION; TH1 CELL; TUBERCULOSIS;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; ANTIMICROBIAL CATIONIC PEPTIDES; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, KNOCKOUT; MYCOBACTERIUM TUBERCULOSIS; SIGNAL TRANSDUCTION; TH1 CELLS; TOLL-LIKE RECEPTORS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SYNTHETIC;

EID: 84896747213     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083884     Document Type: Article

References (44)

1. Andersen P, Doherty TM (2005) The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-662. (Pubitemid 41052152)
2. Rowland R, McShane H (2011) Tuberculosis vaccines in clinical trials. Expert Rev Vaccines 10: 645-658.
3. Cooper AM (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27: 393-422.
4. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850. (Pubitemid 47038186)
5. Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, et al. (2010) A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2: 53ra74.
6. Coler RN, Bertholet S, Pine SO, Orr MT, Reese V, et al. (2012) Therapeutic Immunization against Mycobacterium tuberculosis Is an Effective Adjunct to Antibiotic Treatment. J Infect Dis.
7. Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, et al. (2010) A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5: e13677.
8. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, et al. (2011) Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6: e16333.
9. Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, et al. (2012) The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 188: 2189-2197.
10. Orr MT, Fox CB, Baldwin SL, Sivananthan SJ, Lucas E, et al. (2013) Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release 172: 190-200.
11. Meyer J, McShane H (2013) The next 10 years for tuberculosis vaccines: do we have the right plans in place? Expert Rev Vaccines 12: 443-451.
12. Manicassamy S, Pulendran B (2009) Modulation of adaptive immunity with Toll-like receptors. Semin Immunol 21: 185-193.
13. Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239: 178-196.
14. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, et al. (2009) AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183: 6186-6197.
15. Schwarz TF (2009) Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv Ther 26: 983-998.
16. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6: 769-776. (Pubitemid 43090462)
17. Zhu Q, Egelston C, Vivekanandhan A, Uematsu S, Akira S, et al. (2008) Tolllike receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci U S A 105: 16260-16265.
18. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, et al. (2007) MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol 178: 1164-1171. (Pubitemid 46095190)
19. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, et al. (2010) Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 120: 607-616.
20. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, et al. (2011) Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543-547.
21. Matthews K, Chung NP, Klasse PJ, Moore JP, Sanders RW (2012) Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation. J Immunol 189: 5729-5744.
22. Raman VS, Bhatia A, Picone A, Whittle J, Bailor HR, et al. (2010) Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol 185: 1701-1710.
23. Trinchieri G, Sher A (2007) Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 7: 179-190.
24. Krummen M, Balkow S, Shen L, Heinz S, Loquai C, et al. (2010) Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. J Leukoc Biol 88: 189-199.
25. Moon JJ, Chu HH, Hataye J, Pagan AJ, Pepper M, et al. (2009) Tracking epitope-specific T cells. Nat Protoc 4: 565-581.
26. Moon JJ, Chu HH, Pepper M, McSorley SJ, Jameson SC, et al. (2007) Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 27: 203-213. (Pubitemid 47284919)
27. Hajjar AM, Ernst RK, Fortuno ES, 3rd, Brasfield AS, Yam CS, et al. (2012) Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica. PLoS Pathog 8: e1002963.
28. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, et al. (2010) Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 182: 1073-1079.
29. Mittrucker HW, Steinhoff U, Kohler A, Krause M, Lazar D, et al. (2007) Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A 104: 12434-12439. (Pubitemid 47206155)
30. Derrick SC, Yabe IM, Yang A, Morris SL (2011) Vaccine-induced antituberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 29: 2902-2909.
31. Orr MT, Duthie MS, Windish HP, Lucas EA, Guderian JA, et al. (2013) MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant. Eur J Immunol 43: 2398-2408.
32. Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, et al. (2008) Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol 181: 7948-7957.
33. Olive C (2012) Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Expert Rev Vaccines 11: 237-256.
34. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, et al. (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203: 413-424. (Pubitemid 43290850)
35. Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R (2011) Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 2011: 405310.
36. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, et al. (2005) The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 52: 2313-2322. (Pubitemid 41117415)
37. Makela SM, Strengell M, Pietila TE, Osterlund P, Julkunen I (2009) Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells. J Leukoc Biol 85: 664-672.
38. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, et al. (2006) Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108: 544-550. (Pubitemid 44061354)
39. Mitchell D, Yong M, Schroder W, Black M, Tirrell M, et al. (2010) Dual stimulation of MyD88-dependent Toll-like receptors induces synergistically enhanced production of inflammatory cytokines in murine bone marrow-derived dendritic cells. J Infect Dis 202: 318-329.
40. Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J (2007) Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol 247: 72-84. (Pubitemid 350019447)
41. Gautier G, Humbert M, Deauvieau F, Scuiller M, Hiscott J, et al. (2005) A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 201: 1435-1446. (Pubitemid 40664087)
42. Tada H, Aiba S, Shibata K, Ohteki T, Takada H (2005) Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 73: 7967-7976. (Pubitemid 41740282)
43. Underhill DM (2007) Collaboration between the innate immune receptors dectin-1, TLRs, and Nods. Immunol Rev 219: 75-87. (Pubitemid 47390003)
44. Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJ, van Hout-Kuijer M, et al. (2010) Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 116: 564-574.